J&J’s Stelara Revenue Plummets as Biosimilar Competition Intensifies in 2025

In 2025, Johnson & Johnson's Stelara faces intense competition from multiple biosimilars in the U.S. market, following key patent expirations.

There are now at least nine Stelara biosimilars, with discounts ranging from 46% to 90% off Stelara’s list price; some private labels are offered by PBM affiliates12.

Pharmacy benefit managers, including CVS and Optum, have excluded Stelara from preferred formularies or demoted it to non-preferred tiers, accelerating the shift to biosimilars2.

Stelara's global Q1 2025 sales dropped 33.7% year-over-year to $1.08 billion; U.S. sales declined 29.8%, with international sales dropping 38.9%2.

The entry of these low-cost biosimilars in mid-2025 has sparked a price war similar to what happened with Humira, putting additional pressure on Stelara's revenues1.

J&J's Innovative Medicine unit has offset some of Stelara's decline with growth from newer drugs like Tremfya (+18.2%) and ERLEADA (+11.9%)2.

Newly launched biosimilars include Amgen's Wezlana, Sandoz's Pyzchiva, and Biocon's Yesintek, with some products already available at up to 80% below Stelara's list price3.

Sources:

1. https://www.drugchannels.net/2025/07/the-stelara-biosimilar-price-war-how.html?pfstyle=wp

2. https://www.ainvest.com/news/stelara-s-sales-slump-and-biosimilar-surge-can-johnson-johnson-maintain-dominance-in-immunology-25071010ff05cb389d187e56/

3. https://www.managedhealthcareexecutive.com/view/two-more-stelara-biosimilars-launch